Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14610823 | 0.89 | EPHX2 (0.43) | EPHX2RIPK1HDAC1HDAC6HDAC2 | |
| SCHEMBL14569489 | 0.87 | EPHX2 (0.47) | EPHX2RIPK1ADAM17 | |
| SCHEMBL14557708 | 0.86 | EPHX2 (0.41) | EPHX2RIPK1HDAC1HDAC6HDAC2 | |
| SCHEMBL14569804 | 0.81 | EPHX2 (0.38) | EPHX2RIPK1ADAM17 | |
| SCHEMBL14569488 | 0.81 | EPHX2 (0.40) | EPHX2RIPK1ADAM17 | |
| SCHEMBL14610825 | 0.76 | EPHX2 (0.46) | EPHX2RIPK1ADAM17 | |
| SCHEMBL14557696 | 0.73 | EPHX2 (0.43) | EPHX2RIPK1ADAM17 | |
| SCHEMBL17454944 | 0.73 | RIPK1 (0.69) | EPHX2RIPK1 | |
| SCHEMBL8275419 | 0.73 | RIPK1 (0.69) | EPHX2RIPK1 | |
| SCHEMBL14611020 | 0.72 | EPHX2 (0.39) | EPHX2RIPK1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | EPHX2 3415/4885RIPK1 4081/4885HDAC1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.